Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.43 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.42 |
| ▸ | TUBB | P07437 | 2/20 | 0.42 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.42 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.42 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.42 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.42 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.42 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.42 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.42 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.42 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.42 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.42 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.42 |
| ▸ | TUBB2B | Q9BVA1 | 2/20 | 0.42 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TNKS | O95271 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL119067 | 1.00 | EGFR (0.49) | EGFRHDAC3TUBB4ATUBBTUBA3C | |
| SCHEMBL28474356 | 0.99 | EGFR (0.47) | EGFRHDAC3TUBB4ATUBBTUBA3C | |
| SCHEMBL119065 | 0.87 | EGFR (0.51) | EGFRHDAC3TUBB4ATUBBTUBA3C | |
| SCHEMBL3222440 | 0.86 | EGFR (0.49) | EGFRHDAC3TUBB4ATUBBTUBA3C | |
| SCHEMBL3222436 | 0.86 | EGFR (0.49) | EGFRHDAC3TUBB4ATUBBTUBA3C | |
| SCHEMBL21802302 | 0.83 | EGFR (0.44) | EGFRHDAC3TUBB4ATUBBTUBA3C | |
| SCHEMBL21802303 | 0.83 | EGFR (0.44) | EGFRHDAC3TUBB4ATUBBTUBA3C | |
| SCHEMBL28053687 | 0.81 | EGFR (0.40) | EGFRHDAC3TUBB4ATUBBTUBA3C | |
| Octane SCHEMBL28761136 | 0.80 | EGFR (0.57) | EGFRHDAC3TUBB4ATUBBTUBA3C | |
| SCHEMBL119066 | 0.79 | TDP1 (0.55) | EGFRHDAC3TUBB4ATUBBTUBA3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4251125-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND PROTECTING AGAINST DAMAGE IN CELLS AND TISSUES | F3 Platform Biologics, Inc. (US) | 2023-10-04 | — | — | EP | claimed |
| US-20230000735-A1 | ANTI-WRINKLE COSMETIC COMPOSITION, COMPOSITION SYSTEM AND METHOD FOR COSMETIC SKIN TREATMENT | Natura Cosméticos S.A. (BR) | 2023-01-05 | — | — | US | claimed |
| US-11478409-B2 | Anti-wrinkle cosmetic composition, composition system and method for cosmetic skin treatment | NATURA COSMETICOS S.A. (BR) | 2022-10-25 | — | — | US | claimed |
| WO-2022115360-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND PROTECTING AGAINST DAMAGE IN CELLS AND TISSUES | F3 PLATFORM BIOLOGICS, INC. (US) | 2022-06-02 | — | — | WO | claimed |
| US-20200113795-A1 | COSMETIC COMPOSITION AND PREPARATION METHOD THEREFOR | AMOREPACIFIC CORPORATION (KR) | 2020-04-16 | — | — | US | claimed |
| US-20190167540-A1 | ANTI-WRINKLE COSMETIC COMPOSITION, COMPOSITION SYSTEM AND METHOD FOR COSMETIC SKIN TREATMENT | Natura Cosméticos S.A. (BR) | 2019-06-06 | — | — | US | claimed |
| EP-3466406-A1 | ANTI-WRINKLE COSMETIC COMPOSITION, COMPOSITION SYSTEM AND METHOD FOR COSMETIC SKIN TREATMENT | Natura Cosméticos S.A. (BR) | 2019-04-10 | — | — | EP | claimed |
| US-8152860-B2 | Cosmetic composition for coloring hair comprising a direct hair dye and a carrier system comprising polysaccharides | ROVI COSMETICS INTERNATIONAL GMBH (DE) | 2012-04-10 | — | — | US | claimed |
| EP-1962782-B1 | COSMETIC W/O EMULSIONS WITH ORGANIC SUNSCREENS AND CONJUGATED LINOLEIC ACID | UNILEVER PLC (GB) | 2009-11-04 | — | — | EP | claimed |
| WO-2009069933-A2 | OIL-IN-WATER SOLID COSMETIC COMPOSITION WITH HIGHER STABILITY AGAINST EVAPORATION OF INTERNAL PHASE (WATER) AS WELL AS OUTSTANDING MOISTURIZING EFFECT | AMOREPACIFIC CORPORATION (KR) | 2009-06-04 | — | — | WO | claimed |
| EP-2040667-A1 | MOISTURISING AND SUNSCREEN SKINCARE COMPOSITION | Reckitt & Colman (Overseas) Limited (GB) | 2009-04-01 | — | — | EP | claimed |
| WO-2007144670-A1 | MOISTURISING AND SUNSCREEN SKINCARE COMPOSITION | RECKITT & COLMAN (OVERSEAS) LIMITED (GB) | 2007-12-21 | — | — | WO | claimed |
| US-7208142-B2 | Indanylidene compounds | SYMRISE GMBH & CO. KG (DE) | 2007-04-24 | — | — | US | claimed |
| US-7147841-B2 | Formulation of UV absorbers by incorporation in solid lipid nanoparticles | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 2006-12-12 | — | — | US | claimed |
| EP-1378231-A1 | Formulation of UV absorbers by incorporation in solid lipid nanoparticles | Ciba Specialty Chemicals Holding Inc. (CH) | 2004-01-07 | — | — | EP | claimed |
| US-20030235540-A1 | Formulation of UV absorbers by incorporation in solid lipid nanoparticles | CIBA SPECIALTY CHEMICALS CORP. | 2003-12-25 | — | — | US | claimed |
| US-20020143203-A1 | Novel indanylidene compounds | SYMRISE GMBH & CO. KG (DE) | 2002-10-03 | — | — | US | claimed |
| EP-3698770-B1 | COSMETIC COMPOSITION FOR BLOCKING FINE DUST | LG HOUSEHOLD & HEALTH CARE LTD (KR) | 2024-09-11 | — | — | EP | disclosed |
| WO-1999051220-A1 | METHODS AND COMPOSITIONS FOR REDUCING UV-INDUCED INHIBITION OF COLLAGEN SYNTHESIS IN HUMAN SKIN | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1999-10-14 | — | — | WO | disclosed |
| WO-1998055075-A2 | COMPOSITIONS AND METHODS FOR INHIBITING PHOTOAGING OF SKIN | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1998-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030235540-A1 | Formulation of UV absorbers by incorporation in solid lipid nanoparticles | CUTA, LIPC, AUP1 | EGFR 2607/4885HDAC3 2906/4885TUBB4A 4515/4885 |
| US-20020143203-A1 | Novel indanylidene compounds | CUTA, NISCH, ERCC4 | EGFR 1033/4885HDAC3 591/4885TUBB4A 1909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.